1 0

    FDA Correspondence on Erythritol & Cardiovascular Risk (2023)

    FDA Correspondence on Erythritol & Cardiovascular Risk (2023)

    $89.00 USD
    $89.00 USD
    Sale Sold out
    Request Contents: All correspondence related to FDA’s evaluation of the February 27, 2023 article: “The artificial sweetener erythritol and cardiovascular event risk” by Witkowski et al., including its use in FDA’s June 2023 memorandum.
    • Status: Pending Fast-Track Request
    • Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity

    NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.

    View full details